In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £140.00. The company’s shares closed yesterday at ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review in the U.S. for the treatment of adult patients with ...

AstraZeneca’s share price has fallen a long ... and does not constitute personal advice or a personal recommendation. No content should be relied upon as constituting personal advice or a ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

AstraZeneca is a company with a turbulent history ... who had been instructed to find a name which was memorable, had no associations with other companies, nor was offensive in any language ...

Here are some before and after pictures of the company's wordmark and logo. Here's a look at how the new wordmark and logo will appear on storefronts. Social media users react to Walmart's logo ...

AstraZeneca has reported the first clinical ... to move ahead with a phase 2 programme for its drug, although there’s no doubt it is playing catch-up in the oral PCSK9 inhibitor category with ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute ...

SINGAPORE: Singapore and South Korea launched a logo to be used in events celebrating the 50th anniversary of diplomatic relations between the two countries. The logo, unveiled on Monday (Jan 13 ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...